Drugs /

rbn-2397

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration, PARP7 inhibitor RBN-2397 selectively binds to PARP7 and restores interferon (type 1) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.

Clinical Trials

View Clinical Trials for rbn-2397

Rbn-2397 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating rbn-2397, 1 is phase 1 (1 open).

Malignant solid tumor and mantle cell lymphoma are the most common diseases being investigated in rbn-2397 clinical trials [2].

Drug Details

Synonyms [2]:
rbn 2397, rbn2397, parp7 inhibitor rbn-2397
Drug Categories [2]:
Immunotherapies
Drug Target(s) [2]:
TIPARP
NCIT ID [1]:
C170764

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.